|Published (Last):||13 February 2018|
|PDF File Size:||17.9 Mb|
|ePub File Size:||9.16 Mb|
|Price:||Free* [*Free Regsitration Required]|
Published studies are primarily clinical and epidemiological research but also basic. CiteScore measures average citations received per document published.
Read more. SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact. SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.
Lupus nephritis is a relevant source of morbidity and mortality in patients with systemic lupus erythematosus. The standard therapy of remission induction in severe lupus nephritis is based on the use of monthly intravenous cyclophosphamide. Recent data have established that the maintenance of remission in lupus nephritis can be achieved with azathioprine or mycophenolate mofetil, with less adverse effects than quarterly intravenous cyclophosphamide.
In recent years, a number of controlled randomized clinical trials have been published, opening new therapeutic options in the induction of remission in lupus nephritis, such as less aggressive regimens of intravenous cyclophosphamide or mycophenolate mofetil. Further studies are needed for establishing the optimal therapy of lupus nephritis patients..
ISSN: Open Access Option. Previous article Next article. Issue 4. Pages July - August Download PDF. Corresponding author. This item has received. Article information. Further studies are needed for establishing the optimal therapy of lupus nephritis patients.
Key words:. Lupus nephritis. Palabras clave:. Full text is only aviable in PDF. Jacobson, S. Gange, N. Rose, N. Epidemiology and estimated population burden of selected autoinmune diseases in the United States. Clin Immunol Immunopathol, 84 , pp. Johnson, C. Gordon, R. Palmer, P. The prevalence and incidence of systemic lupus erythematosus in Birmingham. Relationship to ethnicity and country of birth.
Arthritis Rheum, 38 , pp. Cervera, M. Khamashta, J. Font, G. Sebastiani, A. Gil, P. Lavilla, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of patients. Medicine Baltimore , 72 , pp. Morbidity and mortality in systemic lupus erythematosus during a year period: a comparison of early and late manifestations in a cohort of patients.
Medicine Baltimore , 82 , pp. Golbus, W. Lupus nephritis, Classification, prognosis, immunopathogenesis and treatment.
Rheum Dis Clin North Am, 20 , pp. Howie, N. Turhan, D. Powerful morphometric indicator of prognosis in lupus nephritis. QMJ, 96 , pp. Mok, K. Ying, S. Tang, C. Leung, K. Lee, W. Ng, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
Arthritis Rheum. Churg, L. Igaku-Shoin, ,. Weening, V. Schwartz, S. Seshan, C. Alpers, G. Appel, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited.
Kidney International, 65 , pp. Steinberg, S. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum, 34 , pp. Austin 3rd, J. Klippel, J. Balow, N. Steinberg, P. Plotz, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.
N Engl J Med, , pp. Boumpas, H. Austin 3rd, E. Vaughan, J. Klippel, A. Steinberg, C. Yarboro, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.
Lancet, , pp. Illei, H. Austin, M. Crane, L. Collins, M. Gourley, C. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxiciy in patients with lupus nephritis. Ann Intern Med, , pp. Gourley, H. Austin 3rd, D.
A consensus of the Chilean Nephrology and Rheumatology Societies on renal involvement in systemic lupus erythematosus. Valdivia, Chile. Santiago, Chile. Hospital del Salvador. Correspondencia a :.
Published studies are primarily clinical and epidemiological research but also basic. CiteScore measures average citations received per document published. Read more. SRJ is a prestige metric based on the idea that not all citations are the same.